The Synergistic and Opposing Roles of ω-Fatty Acid Hydroxylase (CYP4A11) and ω-1 Fatty Acid Hydroxylase (CYP2E1) in Chronic Liver Disease DOI

H. P.,

Garcia Victor

Published: Oct. 10, 2024

Cytochrome P450 fatty acid hydroxylase consists of members the CYP4 family that ω-hydroxylate acids and CYP2E1 ω-1 hydroxylates acids. Although ω hydroxylation have been thought to play a minor role in metabolism (less than 20%), it plays vital excess liver overload seen fasting, diabetes, metabolic disorder, over-consumption alcohol high-fat diet. This pathway provides anabolic metabolites for gluconeogenesis, succinate, acetate lipogenesis. The CYP4A genes are activated fasting several disorders, suggesting synergistic preventing acid-induced lipotoxicity with consequence increased cholesterol lipogenesis leading Lipid Droplet (LD) deposition. During progression Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), activation Phospholipase A2 (PLA2) releases arachidonic CYP4A11 P450s metabolize produce 20-hydroxyeicosatetraenoic (20-HETE) 19-HETE, respectively. These opposing roles MASLD chronic disease (CLD). report discusses saturated unsaturated their opposite physiological Arachidonic Acid (AA). We finally discuss ethanol disrupting CLD.

Language: Английский

The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment DOI Open Access
Eleni Michalopoulou, J Thymis, Stamatios Lampsas

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(2), P. 428 - 428

Published: Jan. 10, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging global health concern, and it not only the keystone precursor of eventual liver-related morbidity, but also places patients at considerably higher cardiovascular risk, which still a leading cause death in these patients. The most important common underlying pathophysiological mechanisms diseases are primarily related to insulin resistance, chronic inflammation oxidative stress. presence MASLD with (CVD) type 2 diabetes mellitus (T2DM) elevates risk for poor outcomes, thus this review highlights method therapeutic approaches. Given intertwined nature MASLD, T2DM, CVD, there urgent need strategies that address all three conditions. Although lifestyle changes as treatment, medication plays crucial role managing hyperglycemia, enhancing function lowering risk. onset progression should be addressed through multifaceted approach, targeting inflammatory, immune, metabolic, stress, hormonal gutaxis pathways, alongside treatment T2DM. In review, we discuss effects antidiabetic drugs impact on both outcomes affected by T2DM CDV.

Language: Английский

Citations

1
Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD DOI Open Access

Marin Pecani,

P. Andreozzi, Roberto Cangemi

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(8), P. 2750 - 2750

Published: April 16, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty (NAFLD), encompasses a spectrum of diseases characterized by hepatic steatosis, the presence at least one cardiometabolic risk factor, and no other apparent cause. syndrome (MetS) is cluster clinical conditions associated with increased cardiovascular disease, type 2 diabetes, overall morbidity mortality. This narrative review summarizes changes in management people MetS NAFLD/MASLD from screening to therapeutic strategies that have occurred last decades. Specifically, we underline importance considering different impacts simple steatosis advanced fibrosis provide an up-to-date overview on non-invasive diagnostic tests (i.e., imaging serum biomarkers), which now offer acceptable accuracy are globally more accessible. Early detection MASLD top priority it allows for timely interventions, primarily through lifestyle modification. The benefits global multidimensional approach not negligible. Therefore, holistic both conditions, related chronic should be applied improve health longevity.

Language: Английский

Citations

0
Targeting Metabolism: Innovative Therapies for MASLD Unveiled DOI Open Access
Weixin Wang, Xin Gao, Wei Niu

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4077 - 4077

Published: April 25, 2025

The recent introduction of the term metabolic-dysfunction-associated steatotic liver disease (MASLD) has highlighted critical role metabolism in disease’s pathophysiology. This innovative nomenclature signifies a shift from previous designation non-alcoholic fatty (NAFLD), emphasizing condition’s progressive nature. Simultaneously, MASLD become one most prevalent diseases worldwide, highlighting urgent need for research to elucidate its etiology and develop effective treatment strategies. review examines delineates revised definition MASLD, exploring epidemiology pathological changes occurring at various stages disease. Additionally, it identifies metabolically relevant targets within provides summary latest targeted drugs under development, including those clinical some preclinical stages. finishes with look ahead future therapy goal summarizing providing fresh ideas insights.

Language: Английский

Citations

0
The Synergistic and Opposing Roles of ω-Fatty Acid Hydroxylase (CYP4A11) and ω-1 Fatty Acid Hydroxylase (CYP2E1) in Chronic Liver Disease DOI

H. P.,

Garcia Victor

Published: Oct. 10, 2024

Cytochrome P450 fatty acid hydroxylase consists of members the CYP4 family that ω-hydroxylate acids and CYP2E1 ω-1 hydroxylates acids. Although ω hydroxylation have been thought to play a minor role in metabolism (less than 20%), it plays vital excess liver overload seen fasting, diabetes, metabolic disorder, over-consumption alcohol high-fat diet. This pathway provides anabolic metabolites for gluconeogenesis, succinate, acetate lipogenesis. The CYP4A genes are activated fasting several disorders, suggesting synergistic preventing acid-induced lipotoxicity with consequence increased cholesterol lipogenesis leading Lipid Droplet (LD) deposition. During progression Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), activation Phospholipase A2 (PLA2) releases arachidonic CYP4A11 P450s metabolize produce 20-hydroxyeicosatetraenoic (20-HETE) 19-HETE, respectively. These opposing roles MASLD chronic disease (CLD). report discusses saturated unsaturated their opposite physiological Arachidonic Acid (AA). We finally discuss ethanol disrupting CLD.

Language: Английский

Citations

0